Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prudence Ive

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of the International AIDS Society|September 29, 2016
Developing a predictive risk model for first-line antiretroviral therapy failure in South AfricaJulia K Rohr, Prudence Ive, C Robert Horsburgh, et al.
Tropical Medicine & International Health : TM & IH|July 8, 2016
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South AfricaMatthew P Fox, Rebecca Berhanu, Kim Steegen, et al.
AIDS (London, England)|July 9, 2010
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South AfricaMatthew P Fox, Ian M Sanne, Francesca Conradie, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2013
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programsAnne F Luetkemeyer, Michelle A Kendall, Mulinda Nyirenda, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2013
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE StudyAnne F Luetkemeyer, Susan L Rosenkranz, Darlene Lu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2013
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomesRaph L Hamers, Hans L Zaaijer, Carole L Wallis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 6, 2017
Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment OutcomesJulia K Rohr, Prudence Ive, Charles Robert Horsburgh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2011
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in AfricaKim C E Sigaloff, Raph L Hamers, Carole L Wallis, et al.
The Journal of Infectious Diseases|May 21, 2013
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionSaran Vardhanabhuti, Edward P Acosta, Heather J Ribaudo, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of the International AIDS Society|September 29, 2016
Developing a predictive risk model for first-line antiretroviral therapy failure in South AfricaJulia K Rohr, Prudence Ive, C Robert Horsburgh, et al.
Tropical Medicine & International Health : TM & IH|July 8, 2016
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South AfricaMatthew P Fox, Rebecca Berhanu, Kim Steegen, et al.
AIDS (London, England)|July 9, 2010
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South AfricaMatthew P Fox, Ian M Sanne, Francesca Conradie, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2013
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programsAnne F Luetkemeyer, Michelle A Kendall, Mulinda Nyirenda, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 18, 2013
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE StudyAnne F Luetkemeyer, Susan L Rosenkranz, Darlene Lu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2013
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomesRaph L Hamers, Hans L Zaaijer, Carole L Wallis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 6, 2017
Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment OutcomesJulia K Rohr, Prudence Ive, Charles Robert Horsburgh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2011
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in AfricaKim C E Sigaloff, Raph L Hamers, Carole L Wallis, et al.
The Journal of Infectious Diseases|May 21, 2013
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionSaran Vardhanabhuti, Edward P Acosta, Heather J Ribaudo, et al.
Pageof 5